Journal of Infection
Volume 60, Issue 4 , Pages 264-270 , April 2010

Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders

,Accepted 31 January 2010.

References 

  1. Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13:S47–S49
  2. Otag F. False positive HBsAg result in blood donors due to administration of three different recombinant DNA hepatitis B vaccines. Vaccine. 2003;21:3734–3737
  3. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61:623–625
  4. Sabidó M, Gavaldà L, Olona N, Ramon JM. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. Vaccine. 2007;25:7568–7572
  5. Gandhoke I, Gupta S, Lal S, Khare S. Immune response to recombinant hepatitis B vaccination in adults. J Commun Dis. 2003;35:249–255
  6. Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocellular carcinoma caused by hepatitis B virus. Vaccine. 2003;21:4626–4649
  7. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccine. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15:1–8
  8. Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol. 2002 Feb;97(2):435–439
  9. Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology. 2000;31:230–234
  10. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine. 2009;27(1):17–22
  11. Liehl E, Hildebrandt J, Lam C, Mayer P. Prediction of the role of granulocyte–macrophage colony-stimulating factor in animals and man from in vitro results. Eur J Clin Microbiol Infect Dis. 1994;13(Suppl. 2):S9–S17
  12. Tarr PE, Lin R, Mueller EA, Kovarik JM, Guillaume M, Jones TC. Evaluation of tolerability and antibody response after recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine. 1996;14:1199–1204
  13. Kim MJ, Nafziger AN, Harro CD, Keyserling HL, Ramsey KM, Drusano GL, et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine. 2003;21:1174–1179
  14. Belloni C, Pistorio A, Tinelli C, Komakec J, Chirico G, Rovelli D, et al. Early immunisation with hepatitis B vaccine: a five year study. Vaccine. 2000;18:1307–1311
  15. Hussain Z, Ali SS, Husain SA, Raish M, Sharma DR, Kar P. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India. World J Gastroenterol. 2005;11:7165–7168
  16. Oguz Y, Doganci L, Vural A. Seroconversion rates of two different doses of hepatitis B vaccine in Turkish haemodialysis patients. Cent Eur J Public Health. 2001;9:44–45
  17. Estévez ZC, Betancourt AA, Muzio González V, Baile NF, Silva CV, Bernal FH, et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals. 2007;35:115–122
  18. Yucesoy B, Sleijffers A, Kashon M, Garssen J, De Gruijl FR, Boland GJ, et al. IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine. 2002;20:3193–3196
  19. Sleijffers A, Yucesoy B, Kashon M, Garssen J, De Gruijl FR, Boland GJ, et al. Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol. 2003;170:3423–3428
  20. Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine. 1997;15:353–356
  21. Gold Y, Somech R, Mandel D, Peled Y, Reif S. Decreased immuneresponse to hepatitis B eight years after routine vaccination in Israel. Acta Paediatr. 2003;92:1158–1162
  22. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319–1325
  23. Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine. 2004;22:607–610
  24. Anandh U, Bastani B, Ballal S. Granulocyte–macrophage colony stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am J Nephrol. 2000;20:53–56
  25. Evans TG, Schiff M, Graves B, Agosti J, Barritt ML, Garner D, et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol. 2000;54:138–142
  26. Hess G, Kreiter F, Kosters W, Deusch K. The effect of granulocyte–macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat. 1996;3:149–153
  27. Singh NP, Mandal SK, Thakur A, Kapoor D, Anuradha S, Prakash A, et al. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure – results of a prospective, randomized trial. Ren Fail. 2003;25:255–266
  28. Kapoor D, Aggarwal SR, Singh NP, Thakur V, Sarin SK. Granulocyte–macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat. 1999;6:405–409
  29. Hasan MS, Agosti JM, Reynolds KK, Tanzman E, Treanor JJ, Evans TG. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J Infect Dis. 1999;180:2023–2026
  30. Sasaki MG, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte–macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine. 2003;21(31):4545–4549
  31. Kirkpatrick CH, Wilson WEC, Talmage DW. Immunologic studies in human organ transplantation. I. Observation and characterisation of suppressed cutaneous reactivity in uraemia. J Exp Med. 1964;6:727–742
  32. Raska K, Raskova J, Shea SM, Frankel RM, Wood RH, Lifter J, et al. T-cell subsets and cellular immunity in end-stage renal disease. Am J Med. 1983;6:734–740
  33. Meur SC, Haver M, Kurz P, Meyer zum Buschenfeld EKH, Kohler H. Selective blockade of the antigen receptor mediated pathway of T cell activation in patients with impaired immune responses. J Clin Invest. 1987;6:743–749
  34. Dumann HD, Meuer S, Meyer zum Buschenfelde EKH, Kohler H. Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Kidney Int. 1990;6:1164–1168
  35. Gibbons RAS, Martinez OM, Garovoy MR. Altered monocyte function in uraemia. Clin Immunol Immunopathol. 1990;6:66–80
  36. Lieschke GJ, Burgess AW. Granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor. N Engl J Med. 1992;6:28–35
  37. Jones T, Stern A, Lin R. Potential role of granulocyte–macrophage colony stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis. 1994;6:47–53
  38. Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, Hodes RJ, et al. Regulation of immunostimulatory function and costimulatory molecule (B7–1 and B7–2) expression on murine dendritic cells. J Immunol. 1994;152:5208–5219
  39. Markowicz S, Engleman EG. Granulocyte–macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest. 1990;85:955–961
  40. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271–296

PII: S0163-4453(10)00038-1

doi: 10.1016/j.jinf.2010.01.011

Journal of Infection
Volume 60, Issue 4 , Pages 264-270 , April 2010

Article Tools